APO Research
Talk to an analyst

APO RESEARCH · REPORT

Female Contraceptives

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Female Contraceptives Market Outlook and Growth Opportunities 2026

20 December 2025198 pages

Choose your research edition.

Industry ResearchFemale Contraceptives Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Female Contraceptives Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Female Contraceptives Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Female Contraceptives Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Female Contraceptives Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Female Contraceptives market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Female Contraceptives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Female Contraceptives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Female Contraceptives is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Female Contraceptives market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Female Contraceptives market include Teva, Johnson & Johnson, Merck, Mylan, Pfizer, Bayer, Mayer Laboratories, Lupin Pharmaceuticals and Fuji Latex, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Female Contraceptives market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Female Contraceptives and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Female Contraceptives revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Female Contraceptives market.

Female Contraceptives Segment by Company

Teva

Johnson & Johnson

Merck

Mylan

Pfizer

Bayer

Mayer Laboratories

Lupin Pharmaceuticals

Fuji Latex

Female Health Company

Female Contraceptives Segment by Type

Female Contraceptive Devices

Female Contraceptive Drugs

Female Contraceptives Segment by Application

Online Stores

Retail Outlets

Female Contraceptives Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Female Contraceptives status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Female Contraceptives key companies, revenue, market share, and recent developments.

3. To split the Female Contraceptives breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Female Contraceptives market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Female Contraceptives significant trends, drivers, influence factors in global and regions.

6. To analyze Female Contraceptives competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Female Contraceptives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Female Contraceptives and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Female Contraceptives.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Female Contraceptives industry.

Chapter 3: Detailed analysis of Female Contraceptives company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Female Contraceptives in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Female Contraceptives in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Female Contraceptives Industry Trends Table 2. Female Contraceptives Industry Drivers Table 3. Female Contraceptives Industry Opportunities and Challenges Table 4. Female Contraceptives Industry Restraints Table 5. Global Female Contraceptives Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Female Contraceptives Revenue Share by Company (2021-2026) Table 7. Global Female Contraceptives Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Female Contraceptives Key Company Manufacturing Base & Headquarters Table 9. Global Female Contraceptives Company, Product Type & Application Table 10. Global Female Contraceptives Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Female Contraceptives by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Female Contraceptive Devices Table 15. Significant Companies of Female Contraceptive Drugs Table 16. Global Female Contraceptives Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Female Contraceptives Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Female Contraceptives Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Female Contraceptives Sales Value Share by Type (2021-2026) Table 20. Global Female Contraceptives Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Online Stores Table 22. Significant Companies of Retail Outlets Table 23. Global Female Contraceptives Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Female Contraceptives Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Female Contraceptives Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Female Contraceptives Sales Value Share by Application (2021-2026) Table 27. Global Female Contraceptives Sales Value Share by Application (2027-2032) Table 28. Global Female Contraceptives Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Female Contraceptives Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Female Contraceptives Sales Value Share by Region (2021-2026) Table 31. Global Female Contraceptives Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Female Contraceptives Sales Value Share by Region (2027-2032) Table 33. Global Female Contraceptives Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Female Contraceptives Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Female Contraceptives Sales Value Market Share by Country (2021-2026) Table 36. Global Female Contraceptives Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Female Contraceptives Sales Value Market Share by Country (2027-2032) Table 38. Teva Company Information Table 39. Teva Business Overview Table 40. Teva Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Teva Female Contraceptives Product Portfolio Table 42. Teva Recent Development Table 43. Johnson & Johnson Company Information Table 44. Johnson & Johnson Business Overview Table 45. Johnson & Johnson Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Johnson & Johnson Female Contraceptives Product Portfolio Table 47. Johnson & Johnson Recent Development Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Merck Female Contraceptives Product Portfolio Table 52. Merck Recent Development Table 53. Mylan Company Information Table 54. Mylan Business Overview Table 55. Mylan Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Mylan Female Contraceptives Product Portfolio Table 57. Mylan Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Pfizer Female Contraceptives Product Portfolio Table 62. Pfizer Recent Development Table 63. Bayer Company Information Table 64. Bayer Business Overview Table 65. Bayer Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Bayer Female Contraceptives Product Portfolio Table 67. Bayer Recent Development Table 68. Mayer Laboratories Company Information Table 69. Mayer Laboratories Business Overview Table 70. Mayer Laboratories Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Mayer Laboratories Female Contraceptives Product Portfolio Table 72. Mayer Laboratories Recent Development Table 73. Lupin Pharmaceuticals Company Information Table 74. Lupin Pharmaceuticals Business Overview Table 75. Lupin Pharmaceuticals Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Lupin Pharmaceuticals Female Contraceptives Product Portfolio Table 77. Lupin Pharmaceuticals Recent Development Table 78. Fuji Latex Company Information Table 79. Fuji Latex Business Overview Table 80. Fuji Latex Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Fuji Latex Female Contraceptives Product Portfolio Table 82. Fuji Latex Recent Development Table 83. Female Health Company Company Information Table 84. Female Health Company Business Overview Table 85. Female Health Company Female Contraceptives Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Female Health Company Female Contraceptives Product Portfolio Table 87. Female Health Company Recent Development Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Female Contraceptives Product Image Figure 2. Global Female Contraceptives Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Female Contraceptives Market Size (2021-2032) & (US$ Million) Figure 4. Global Female Contraceptives Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Female Contraceptive Devices Image Figure 8. Female Contraceptive Drugs Image Figure 9. Global Female Contraceptives Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Female Contraceptives Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Female Contraceptives Sales Value Share by Type (2021-2032) Figure 12. Online Stores Image Figure 13. Retail Outlets Image Figure 14. Global Female Contraceptives Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Female Contraceptives Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Female Contraceptives Sales Value Share by Application (2021-2032) Figure 17. Global Female Contraceptives Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Female Contraceptives Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Female Contraceptives Sales Value (2021-2032) & (US$ Million) Figure 20. North America Female Contraceptives Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Female Contraceptives Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Female Contraceptives Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Female Contraceptives Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Female Contraceptives Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Female Contraceptives Sales Value (2021-2032) & (US$ Million) Figure 26. South America Female Contraceptives Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Female Contraceptives Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Female Contraceptives Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Female Contraceptives Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Female Contraceptives Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Female Contraceptives Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Female Contraceptive Devices
  • Female Contraceptive Drugs
Applications
  • Online Stores
  • Retail Outlets
Companies covered
  • Teva
  • Johnson & Johnson
  • Merck
  • Mylan
  • Pfizer
  • Bayer
  • Mayer Laboratories
  • Lupin Pharmaceuticals
  • Fuji Latex
  • Female Health Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Female Contraceptives Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Female Contraceptives Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Female Contraceptives Market Dynamics
  1. 2.1 Female Contraceptives Industry Trends
  2. 2.2 Female Contraceptives Industry Drivers
  3. 2.3 Female Contraceptives Industry Opportunities and Challenges
  4. 2.4 Female Contraceptives Industry Restraints
3 Female Contraceptives Market by Company
  1. 3.1 Global Female Contraceptives Company Revenue Ranking in 2025
  2. 3.2 Global Female Contraceptives Revenue by Company (2021-2026)
  3. 3.3 Global Female Contraceptives Company Ranking (2024-2026)
  4. 3.4 Global Female Contraceptives Company Manufacturing Base and Headquarters
  5. 3.5 Global Female Contraceptives Company Product Type and Application
  6. 3.6 Global Female Contraceptives Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Female Contraceptives Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Female Contraceptives Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Female Contraceptives Market by Type
  1. 4.1 Female Contraceptives Type Introduction
  2. 4.1.1 Female Contraceptive Devices
  3. 4.1.2 Female Contraceptive Drugs
  4. 4.2 Global Female Contraceptives Sales Value by Type
  5. 4.2.1 Global Female Contraceptives Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Female Contraceptives Sales Value by Type (2021-2032)
  7. 4.2.3 Global Female Contraceptives Sales Value Share by Type (2021-2032)
5 Female Contraceptives Market by Application
  1. 5.1 Female Contraceptives Application Introduction
  2. 5.1.1 Online Stores
  3. 5.1.2 Retail Outlets
  4. 5.2 Global Female Contraceptives Sales Value by Application
  5. 5.2.1 Global Female Contraceptives Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Female Contraceptives Sales Value by Application (2021-2032)
  7. 5.2.3 Global Female Contraceptives Sales Value Share by Application (2021-2032)
6 Female Contraceptives Regional Value Analysis
  1. 6.1 Global Female Contraceptives Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Female Contraceptives Sales Value by Region (2021-2032)
  3. 6.2.1 Global Female Contraceptives Sales Value by Region: 2021-2026
  4. 6.2.2 Global Female Contraceptives Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Female Contraceptives Sales Value (2021-2032)
  7. 6.3.2 North America Female Contraceptives Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Female Contraceptives Sales Value (2021-2032)
  10. 6.4.2 Europe Female Contraceptives Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Female Contraceptives Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Female Contraceptives Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Female Contraceptives Sales Value (2021-2032)
  16. 6.6.2 South America Female Contraceptives Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Female Contraceptives Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Female Contraceptives Sales Value Share by Country, 2025 VS 2032
7 Female Contraceptives Country-level Value Analysis
  1. 7.1 Global Female Contraceptives Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Female Contraceptives Sales Value by Country (2021-2032)
  3. 7.2.1 Global Female Contraceptives Sales Value by Country (2021-2026)
  4. 7.2.2 Global Female Contraceptives Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Female Contraceptives Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Female Contraceptives Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Female Contraceptives Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Female Contraceptives Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Female Contraceptives Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Female Contraceptives Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Female Contraceptives Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Female Contraceptives Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Female Contraceptives Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Female Contraceptives Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Female Contraceptives Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Female Contraceptives Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Female Contraceptives Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Female Contraceptives Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Female Contraceptives Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Female Contraceptives Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Female Contraceptives Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Female Contraceptives Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Female Contraceptives Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Female Contraceptives Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Female Contraceptives Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Female Contraceptives Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Female Contraceptives Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Female Contraceptives Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Female Contraceptives Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Female Contraceptives Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Female Contraceptives Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Female Contraceptives Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Female Contraceptives Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Female Contraceptives Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Female Contraceptives Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Female Contraceptives Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Female Contraceptives Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Female Contraceptives Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Female Contraceptives Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Female Contraceptives Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Female Contraceptives Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Female Contraceptives Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Female Contraceptives Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Female Contraceptives Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Female Contraceptives Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Female Contraceptives Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Female Contraceptives Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Mayer Laboratories
  38. 8.7.1 Mayer Laboratories Company Information
  39. 8.7.2 Mayer Laboratories Business Overview
  40. 8.7.3 Mayer Laboratories Female Contraceptives Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mayer Laboratories Female Contraceptives Product Portfolio
  42. 8.7.5 Mayer Laboratories Recent Developments
  43. 8.8 Lupin Pharmaceuticals
  44. 8.8.1 Lupin Pharmaceuticals Company Information
  45. 8.8.2 Lupin Pharmaceuticals Business Overview
  46. 8.8.3 Lupin Pharmaceuticals Female Contraceptives Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lupin Pharmaceuticals Female Contraceptives Product Portfolio
  48. 8.8.5 Lupin Pharmaceuticals Recent Developments
  49. 8.9 Fuji Latex
  50. 8.9.1 Fuji Latex Company Information
  51. 8.9.2 Fuji Latex Business Overview
  52. 8.9.3 Fuji Latex Female Contraceptives Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fuji Latex Female Contraceptives Product Portfolio
  54. 8.9.5 Fuji Latex Recent Developments
  55. 8.10 Female Health Company
  56. 8.10.1 Female Health Company Company Information
  57. 8.10.2 Female Health Company Business Overview
  58. 8.10.3 Female Health Company Female Contraceptives Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Female Health Company Female Contraceptives Product Portfolio
  60. 8.10.5 Female Health Company Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst